Reports Q3 revenue $ $45.1M , consensus $43.48M .”Our third quarter results reflect our focused execution to drive growth in the business while steadily improving our operating leverage. In addition, we are excited to announce the market release of Nanoplasty(TM) 3D MIS System, our first entry into the osteotomy market,” said John T. Treace, CEO and Founder of Treace. “We believe this innovative new system, combined with our market leading Lapiplasty(R), Adductoplasty(R) and robust pipeline of future technology and procedure offerings, will further drive penetration into the overall bunion market and continue to expand our surgeon customer base through 2025 and beyond.”
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TMCI:
- Treace Medical comments on CMS final rule for hospital outpatient, ASC settings
- Treace Medical announces limited release of Nanoplasty 3D MIS Bunion Correction
- TMCI Upcoming Earnings Report: What to Expect?
- Treace Medical participates in a conference call with BTIG
- Treace Medical Sues Stryker Over Patent Infringement